Ocera Therapeutics Promotes Michael Byrnes To CFO - Quick Facts

(RTTNews) - Ocera Therapeutics, Inc. (OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, has appointed Michael Byrnes as chief financial officer.

Byrnes has served as vice president, finance at Ocera since June 2014. Earlier to Ocera, Byrnes held various corporate finance and accounting roles of increasing responsibility, most recently serving as corporate controller of Maxygen, Inc.

"Michael's exemplary combination of business acumen, professionalism and integrity are central to the financial management of the company and his guidance is highly valued by the senior management team and board of directors," said Linda S. Grais, M.D., chief executive officer of Ocera. "We also thank Sharon Tetlow, who has served as acting chief financial officer since June 2014, for her many contributions to our growth as a public company and to our fundraising activities in mid-2014. Sharon stepped in at a critical time for Ocera, and now leaves the company in good hands with Mike as CFO."